Intake of high doses of beta-carotene in food has been associated in some observational studies with a decreased incidence of cancer. A clinical trial was planned comparing the incidence of cancer in a group taking beta-carotene in capsule form compared with a group taking beta-carotene placebo capsules. One issue in planning such a study is which preparation to use for the beta-carotene capsules. Four preparations were considered: (1) Solatene (30-mg capsules), (2) Roche (60-mg capsules), (3) Badische Anilin und Soda Fabrik (BASF) (30-mg capsules), and
(4) BASF (60-mg capsules). To test efficacy of the four agents in raising plasma-carotene levels, a small bioavailability study was conducted. After two consecutive-day fasting blood samples, 23 volunteers were randomized to one of the four preparations, taking 1 pill every other day for 12 weeks. The primary endpoint was level of plasma carotene attained after moderately prolonged steady ingestion. For this purpose, blood samples were drawn at $6,8,10,$ and 12 weeks, with results given in Data Set BETACAR.DAT at www.cengagebrain.com. The format of the data is given in Table 12.35.
Is there a significant difference in bioavailability of the four different preparations? Use ANOVA methods to assess this based on the 6 -week data in comparison with baseline.